Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent

Fonte Standard Gras
Identifiant

Unité de recherche

INNOSUISSE

Numéro de projet

7783.1;4 EPRP-IW

Titre du projet

Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent

Titre du projet anglais

Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Description succincte	-	-	-
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Description succincte (Anglais)	Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent
Résumé des résultats (Abstract) (Anglais)	The project deals with the Precipitation with Compressed Antisolvent (PCA) technique, i.e. a particle formation process that exploits the properties of a dense gas, typically near-critical carbon dioxide, to precipitate the product out of an organic solution. The main goals are (i) to deepen the understanding of the science and technology of PCA through experimental and theoretical work, and (ii) to apply PCA to the formation of micro- and nano-particles of products of pharmaceutical relevance, more specifically to the precipitation of drug and drug-polymer-composites formulations for pulmonary delivery and controlled drug release, featuring enhanced solubility or surface coating for prevention of irritations or for taste masking purposes. Improvements in such technological areas would have a tremendous impact on the business of Novartis Pharma. ETH Zurich and Novartis Pharma have complementary expertise and are ideal partners to guarantee a high probability of success to the project.

Catégorie

Texte

Description succincte
(Anglais)

Engineering bio-pharmaceutical micro- and nano-particles using supercritical carbon dioxide as anti-solvent

Résumé des résultats (Abstract)
(Anglais)

The project deals with the Precipitation with Compressed Antisolvent (PCA) technique, i.e. a particle formation process that exploits the properties of a dense gas, typically near-critical carbon dioxide, to precipitate the product out of an organic solution. The main goals are (i) to deepen the understanding of the science and technology of PCA through experimental and theoretical work, and (ii) to apply PCA to the formation of micro- and nano-particles of products of pharmaceutical relevance, more specifically to the precipitation of drug and drug-polymer-composites formulations for pulmonary delivery and controlled drug release, featuring enhanced solubility or surface coating for prevention of irritations or for taste masking purposes. Improvements in such technological areas would have a tremendous impact on the business of Novartis Pharma. ETH Zurich and Novartis Pharma have complementary expertise and are ideal partners to guarantee a high probability of success to the project.